SPON1 is an independent prognostic biomarker for ovarian cancer

J Ovarian Res. 2023 May 13;16(1):95. doi: 10.1186/s13048-023-01180-8.

Abstract

Background: Ovarian cancer has the worst outcome among gynecological malignancies; therefore, biomarkers that could contribute to the early diagnosis and/or prognosis prediction are urgently required. In the present study, we focused on the secreted protein spondin-1 (SPON1) and clarified the prognostic relevance in ovarian cancer.

Methods: We developed a monoclonal antibody (mAb) that selectively recognizes SPON1. Using this specific mAb, we determined the expression of SPON1 protein in the normal ovary, serous tubal intraepithelial carcinoma (STIC), and ovarian cancer tissues, as well as in various normal adult tissues by immunohistochemistry, and verified its clinicopathological significance in ovarian cancer.

Results: The normal ovarian tissue was barely positive for SPON1, and no immunoreactive signals were detected in other healthy tissues examined, which was in good agreement with data obtained from gene expression databases. By contrast, upon semi-quantification, 22 of 242 ovarian cancer cases (9.1%) exhibited high SPON1 expression, whereas 64 (26.4%), 87 (36.0%), and 69 (28.5%) cases, which were designated as SPON1-low, possessed the moderate, weak, and negative SPON1 expression, respectively. The STIC tissues also possessed SPON1-positive signals. The 5-year recurrence-free survival (RFS) rate in the SPON1-high group (13.6%) was significantly lower than that in the SPON1-low group (51.2%). In addition, high SPON1 expression was significantly associated with several clinicopathological variables. Multivariable analysis revealed that high SPON1 was an independent prognostic factor for RFS of ovarian cancer.

Conclusions: SPON1 represents a prognostic biomarker for ovarian cancer, and the anti-SPON1 mAb could be valuable as an outcome predictor.

Keywords: F-spondin; Gynecological cancer; Prognosis; Recurrence; Spondin-1.

MeSH terms

  • Adult
  • Biomarkers
  • Biomarkers, Tumor / metabolism
  • Cystadenocarcinoma, Serous* / pathology
  • Fallopian Tube Neoplasms* / pathology
  • Female
  • Humans
  • Ovarian Neoplasms* / genetics
  • Prognosis

Substances

  • Biomarkers
  • Biomarkers, Tumor